STOCK TITAN

Farallon group discloses 7.8% Assembly Biosciences (ASMB) stake and warrant holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Assembly Biosciences, Inc. is the subject of an amended Schedule 13G filing by a group of Farallon-managed investment funds and related entities. As of the date requiring this filing, the Farallon Funds together hold 1,227,590 Shares of Assembly Biosciences common stock.

The group also holds 510,205 Class A Warrants and 510,205 Class B Warrants, each currently treated as not exercisable for beneficial ownership purposes because of a 4.99% Beneficial Ownership Limitation and, for the Class B Warrants, an exercise date beginning on November 15, 2026. Certain Farallon entities and individual managers report beneficial ownership of up to 7.8% of the class.

This amendment mainly updates who is deemed a beneficial owner. Effective January 1, 2026, Avner A. Husen became a member or manager of the Farallon general partners and may be deemed a beneficial owner, while, effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles and may no longer be deemed beneficial owners. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Assembly Biosciences.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/09/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/09/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/09/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:02/09/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/09/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/09/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:02/09/2026
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/09/2026
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

FAQ

How much of Assembly Biosciences (ASMB) stock do the Farallon Funds report owning?

The Farallon Funds report beneficial ownership of 1,227,590 Shares of Assembly Biosciences common stock. Several related entities and individuals report this stake, with certain reporting persons disclosing ownership of up to 7.8% of the outstanding class.

What warrants on Assembly Biosciences shares do the Farallon Funds hold?

The Farallon Funds hold 510,205 Class A Warrants and 510,205 Class B Warrants, each exercisable to purchase one Share. For reporting, these 1,020,410 Warrants are currently treated as not exercisable within 60 days due to a Beneficial Ownership Limitation.

What is the 4.99% Beneficial Ownership Limitation mentioned in the ASMB filing?

The warrants held by the Farallon Funds contain a 4.99% Beneficial Ownership Limitation. They may not be exercised if, after exercise, the reporting persons would beneficially own more than 4.99% of Assembly Biosciences’ outstanding shares as determined under Section 13(d).

Why did Farallon file Amendment No. 1 to its Schedule 13G for ASMB?

Amendment No. 1 updates which individuals are deemed beneficial owners of ASMB shares held by the Farallon Funds. Avner A. Husen became a member or manager of the Farallon general partners, while Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles.

Are the Farallon Funds seeking control of Assembly Biosciences according to this filing?

The reporting group certifies the securities “were not acquired and are not held” for changing or influencing the control of Assembly Biosciences. They state the holdings are not in connection with any control-related transaction, other than activities solely tied to certain nomination rules.

Under which SEC rule is this Schedule 13G/A for Assembly Biosciences filed?

The reporting persons state they are filing under Rule 13d-1(c). This rule applies to certain passive investors who exceed ownership reporting thresholds but certify that their holdings are not for the purpose of changing or influencing control of the issuer.
Assembly Bioscie

NASDAQ:ASMB

View ASMB Stock Overview

ASMB Rankings

ASMB Latest News

ASMB Latest SEC Filings

ASMB Stock Data

457.96M
10.58M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO